AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06526208
Drug: MB-IMP
RxNorm normalized name: Ionosol-MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
Trial: NCT05984004
Drug: 0.9% NaCl isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
Trial: NCT05018221
Drug: Placebo capsule (Vitamin K1)
RxNorm normalized name: vitamin K1 Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered 3 times per week following the subject's hemodialysis session.
Trial: NCT05610332
Drug: FLOT scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w
Trial: NCT05397938
Drug: JMT103 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
Trial: NCT04928430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion
Trial: NCT05186194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04976127
Drug: Talineuren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
Trial: NCT04952259
Drug: Shexiang Tongxin Dropping Pills + routine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral+percutaneous coronary intervention
Trial: NCT06396390
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Trial: NCT06566482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
Trial: NCT06243393
Drug: Physicians Choice (PhC).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to oncologic guidelines.
Trial: NCT05970679
Drug: DW1125 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Atorvastatin 10/5 mg placebo
Trial: NCT05970679
Drug: DW1125A placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5mg placebo
Trial: NCT05970679
Drug: DW1125E placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg placebo
Trial: NCT05970679
Drug: DW1125A-1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg placebo
Trial: NCT06098456
Drug: EGCG, FA, HA, B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
Trial: NCT05816265
Drug: IV Iron Infusion Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
Trial: NCT05931263
Drug: C-BEAM Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidemide，carmustine, etoposide, cytarabine, and melphalan
Trial: NCT05931263
Drug: BEAM Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carmustine, etoposide, cytarabine, and melphalan
Trial: NCT05502549
Drug: CB03-154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB03-154 tablet once daily.
Trial: NCT05502549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily.
Trial: NCT05045508
Drug: OC-01 (varenicline 0.6mg/ml) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
Trial: NCT05045508
Drug: Placebo (vehicle) Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) nasal spray \[control\]
Trial: NCT05621161
Drug: Postoperative analgesia management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
Trial: NCT05143463
Drug: NS101 IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Trial: NCT05966233
Drug: R-DHAP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1
Trial: NCT05966233
Drug: Pola-R-DHAP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1
Trial: NCT06372678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00032526
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05545475
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Trial: NCT05063253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, SC, once weekly
Trial: NCT06277128
Drug: WS016 3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
Trial: NCT06277128
Drug: WS016 6g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
Trial: NCT06277128
Drug: WS016 12g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
Trial: NCT06277128
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
Trial: NCT05672563
Drug: Saline infusion sonography for evaluation of cesarean scar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
Trial: NCT06071416
Drug: Biphasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: appliaction of BCP bone substitute
Trial: NCT04957901
Drug: modified BFM-95 protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
Trial: NCT04861142
Drug: Anti-osteoporotic medication( alendronate or denosumab)
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of anti-osteoporotic medication (alendronate or denosumab)
Trial: NCT05626569
Drug: PD-1 combined with SBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
Trial: NCT04960215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A soft gelatin capsule containing soy oil, 5 capsules a day.
Trial: NCT05012423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered as oral capsules.
Trial: NCT05012423
Drug: ECC0509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
Trial: NCT05012423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be given orally during each dosing day.
Trial: NCT05012423
Drug: ECC0509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC0509 1 mg and 10 mg capsules
Trial: NCT05395143
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Trial: NCT05395143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Trial: NCT05399888
Drug: BIIB080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05399888
Drug: BIIB080-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03787290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive a single subcutaneous injection of saline
Trial: NCT05251662
Drug: IBI305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg/kg IV d1 Q3W
Trial: NCT01240382
Drug: 3% DE-089 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05419674
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT01533532
Drug: KLH-2109
RxNorm normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533532
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06443671
Drug: CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.
Trial: NCT05322096
Drug: RGH-706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules~Oral administration
Trial: NCT05322096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules~Oral administration
Trial: NCT05093582
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
Trial: NCT04959448
Drug: DUPIXENT®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer a single dose of XZP-3621 tablet after a low-fat meal.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Trial: NCT05034120
Drug: XZP-3621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
Trial: NCT05350020
Drug: Hydrocortisone 100mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
Trial: NCT04936490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/d
Trial: NCT06244368
Drug: GVM±R regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.
Trial: NCT04990440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo IV.
Trial: NCT05830045
Drug: QLP2117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03548246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo for 2 years.
Trial: NCT03548246
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
Trial: NCT05630196
Drug: LY3857210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05630196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05204784
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
Trial: NCT05007808
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel for topical administration
Trial: NCT00533247
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04679883
Drug: 5% GLH8NDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% GLH8NDE as eye drops
Trial: NCT04679883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as eye drops
Trial: NCT06479473
Drug: Chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
Trial: NCT06387368
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Trial: NCT06387368
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Trial: NCT05235230
Drug: Reference product (R) 25 mg Film Coated Tablets
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference product (R) 25 mg Film Coated Tablets
Trial: NCT05390892
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide, liraglutide, semaglutide
Trial: NCT05134441
Drug: Placebo matching IMU-838 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Trial: NCT06481787
Drug: Zuojin Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuojin Pills should be taken 30min after breakfast and dinner.
Trial: NCT05251584
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Trial: NCT05513924
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months.
Trial: NCT04072874
Drug: Experimental topical (Curaleish Topical)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
Trial: NCT04755868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients